Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Stoke Therapeutics, Inc. - Common Stock
(NQ:
STOK
)
30.90
-0.84 (-2.65%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Stoke Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 12, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
A Look Ahead: Stoke Therapeutics's Earnings Forecast
↗
August 11, 2025
Via
Benzinga
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
August 11, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts
↗
January 08, 2025
Via
Benzinga
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
August 11, 2025
From
Biogen Inc.
Via
GlobeNewswire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
August 07, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
August 06, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 22, 2025
Via
Benzinga
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
↗
July 22, 2025
Via
Benzinga
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
July 18, 2025
Via
Benzinga
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
July 10, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
July 10, 2025
From
Biogen Inc.
Via
GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals
↗
May 29, 2025
STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's...
Via
Chartmill
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
May 13, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
↗
May 01, 2025
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.
Via
Investor's Business Daily
Topics
Earnings
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics
↗
March 18, 2025
Via
Benzinga
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 18, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces CEO Transition
March 18, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
February 26, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
↗
February 18, 2025
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Via
Benzinga
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
February 18, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
February 18, 2025
From
Biogen Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 11, 2025
Via
Benzinga
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
January 07, 2025
From
Stoke Therapeutics
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
